Activity of Meropenem-Vaborbactam against Bacterial Isolates Causing Pneumonia in Patients in US Hospitals during 2014 to 2018

被引：28
作者：
Carvalhaes, Cecilia G. [1 ]
Shortridge, Dee [1 ]
Sader, Helio S. [1 ]
Castanheira, Mariana [1 ]
机构：
[1] JMI Labs, North Liberty, IA 52317 USA
来源：
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2020年 / 64卷 / 03期
关键词：
CPE; CRE; Enterobacterales; Enterobacteriaceae; HAP; Pseudomonas aeruginosa; VAP; carbapenemase; hospital-acquired pneumonia; ventilator-acquired pneumonia; VENTILATOR-ASSOCIATED PNEUMONIA; ENTEROBACTERIACEAE; MORTALITY; RPX7009; SAFETY;
D O I：
10.1128/AAC.02177-19
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
Meropenem-vaborbactam is approved to treat hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), in Europe. Meropenem-vaborbactam activity was evaluated against 3,193 Pseudomonas aeruginosa and 4,790 Enterobacterales isolates causing pneumonia, including VAP, in hospitalized patients in the United States. Susceptibility testing was performed by using the broth microdilution method, and all carbapenem-resistant isolates were submitted for whole-genome sequencing. Meropenem-vaborbactam exhibited almost complete activity against Enterobacterales (>99.9% susceptible), including carbapenem-resistant Enterobacterales (CRE), and was also very active against P. aeruginosa isolates (89.5% susceptible).
引用
收藏
页数：7
相关论文
共 40 条
[21]   How to treat VAP due to MDR pathogens in ICU patients [J].
Garnacho-Montero J. ;
Corcia-Palomo Y. ;
Amaya-Villar R. ;
Martin-Villen L. .
BMC Infectious Diseases, 14 (1)
[22]   Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of the β-Lactamase Inhibitor Vaborbactam (RPX7009) in Healthy Adult Subjects [J].
Griffith, David C. ;
Loutit, Jeffery S. ;
Morgan, Elizabeth E. ;
Durso, Stephanie ;
Dudley, Michael N. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (10) :6326-6332
[23]   In Vitro Activity of Meropenem-Vaborbactam against Clinical Isolates of KPC-Positive Enterobacteriaceae [J].
Hackel, Meredith A. ;
Lomovskaya, Olga ;
Dudley, Michael N. ;
Karlowsky, James A. ;
Sahm, Daniel F. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (01)
[24]   Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases [J].
Hecker, Scott J. ;
Reddy, K. Raja ;
Totrov, Maxim ;
Hirst, Gavin C. ;
Lomovskaya, Olga ;
Griffith, David C. ;
King, Paula ;
Tsivkovski, Ruslan ;
Sun, Dongxu ;
Sabet, Mojgan ;
Tarazi, Ziad ;
Clifton, Matthew C. ;
Atkins, Kateri ;
Raymond, Amy ;
Potts, Kristy T. ;
Abendroth, Jan ;
Boyer, Serge H. ;
Loutit, Jeffrey S. ;
Morgan, Elizabeth E. ;
Durso, Stephanie ;
Dudley, Michael N. .
JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (09) :3682-3692
[25]  
Jacob JT, 2013, MMWR-MORBID MORTAL W, V62, P165
[26]  
Kalil AC, 2016, CLIN INFECT DIS, V63, pE61, DOI 10.1093/cid/ciw353
[27]   Economic Impact of Ventilator-Associated Pneumonia in a Large Matched Cohort [J].
Kollef, Marin H. ;
Hamilton, Cindy W. ;
Ernst, Frank R. .
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2012, 33 (03) :250-256
[28]  
Lomovskaya O, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/AAC.01443-17, 10.1128/aac.01443-17]
[29]   Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance [J].
Magiorakos, A. -P. ;
Srinivasan, A. ;
Carey, R. B. ;
Carmeli, Y. ;
Falagas, M. E. ;
Giske, C. G. ;
Harbarth, S. ;
Hindler, J. F. ;
Kahlmeter, G. ;
Olsson-Liljequist, B. ;
Paterson, D. L. ;
Rice, L. B. ;
Stelling, J. ;
Struelens, M. J. ;
Vatopoulos, A. ;
Weber, J. T. ;
Monnet, D. L. .
CLINICAL MICROBIOLOGY AND INFECTION, 2012, 18 (03) :268-281
[30]   Determinants of prescription and choice of empirical therapy for hospital-acquired and ventilator-associated pneumonia [J].
Rello, J. ;
Ulldemolins, M. ;
Lisboa, T. ;
Koulenti, D. ;
Manez, R. ;
Martin-Loeches, I. ;
De Waele, J. J. ;
Putensen, C. ;
Guven, M. ;
Deja, M. ;
Diaz, E. .
EUROPEAN RESPIRATORY JOURNAL, 2011, 37 (06) :1332-1339
1234